Clinical Trials Logo

Gastric Cancer clinical trials

View clinical trials related to Gastric Cancer.

Filter by:

NCT ID: NCT02510469 Recruiting - Gastric Cancer Clinical Trials

Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells

Start date: July 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after adjuvant chemotherapy in progressive gastric cancer patients with positive exfoliative cancer cells.

NCT ID: NCT02509806 Recruiting - Gastric Cancer Clinical Trials

Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer

Start date: July 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after first-line chemotherapy in Postoperative Recurrence / Metastasis Progressive Gastric Cancer.

NCT ID: NCT02504229 Recruiting - Gastric Cancer Clinical Trials

DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment

Start date: November 2014
Phase: Phase 2
Study type: Interventional

This study evaluates the therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with S-1 ((Tegafur, Gimeracil, and Oteracil Potassium) and oxaliplatin adjuvant chemotherapy in locally advanced unresectable or metastaticgastric cancer. Half of participants will receive DC-CIK combined with S-1 and oxaliplatin adjuvant chemotherapy,while the other half will receive S-1 and oxaliplatin adjuvant chemotherapy served as controls.

NCT ID: NCT02461407 Recruiting - Gastric Cancer Clinical Trials

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

Start date: June 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.

NCT ID: NCT02457624 Recruiting - Gastric Cancer Clinical Trials

Gastric Cancer Screening Quality Improvement System Establishment

Start date: March 2008
Phase: N/A
Study type: Observational [Patient Registry]

Experienced endoscopists will perform endoscopy during the study period and the detection rate of gastric premalignant lesion, correlation between endoscopic and serologic diagnosis of premalignant lesions and inter-observer agreement rate will be analyzed before and after the education.

NCT ID: NCT02436395 Recruiting - Gastric Cancer Clinical Trials

Povidone-iodine and the Normal Saline Cleaning the Incision for the SSIs

Start date: May 2015
Phase: N/A
Study type: Interventional

Surgical site infections (SSIs) is one of the most common complications of upper abdominal surgery. Previous studies found that type of surgical incision, emergency operation or not, surgical duration, age of patient, body mass index, malignance duration, malnutrition, complications (diabetes, shock, anemia et al) and drug (Long-term use of corticosteroids) are closely associated with the incidence of SSIs. The general incidence rate of SSIs was about 5% to 40%, although using the preoperative skin disinfectant and other methods to prevent and reduce the SSIs. And for the gastrointestinal surgery, due to the potential risk of infection, SSIs is an important problem which cannot be ignored. On the other hand, gastric cancer is one of the most common digestive system tumors, and gastrectomy is the primary therapeutic options. Therefore, it is important to compare the whether the different liquid (1% povidone-iodine solution or the 0.9% normal saline) wash the incision can influent the incidence of the SSIs.

NCT ID: NCT02436018 Recruiting - Gastric Cancer Clinical Trials

WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy

Start date: March 2015
Phase: N/A
Study type: Interventional

Low pulse oximetry is the most common adverse events during sedation for upper gastrointestinal endoscopy. The main reason is the glossoptosis after sedation. In present study a new designed nasopharyngeal airway embedded with jet ventilation catheter(WEI NASAL JET) will be utilized in order to reduce the hypoxia. At the same time the safety will be evaluated.

NCT ID: NCT02426762 Recruiting - Colorectal Cancer Clinical Trials

Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic Surgery

Start date: February 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the short-term effect of sealant-assisted skin closure in prevention of surgical site infection after laparoscopic surgery.

NCT ID: NCT02423278 Recruiting - Gastric Cancer Clinical Trials

The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer

Start date: January 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the effect of extensive lymphadenectomy procedure in treatment of gastric cancer. This study is designed as a open-label, multi-centers, randomized controlled trial. The overall survival and free disease survival are primary outcomes, with postoperative complication, hospital charges, and life quality as secondary outcomes.

NCT ID: NCT02401971 Recruiting - Gastric Cancer Clinical Trials

Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer

ITAGC
Start date: August 2014
Phase: Phase 4
Study type: Interventional

Recent clinical studies have demonstrated a reduction of irinotecan (CPT-11) gastrointestinal toxicities when the CPT-11 is administered in combination with thalidomide in patients with diagnosis of gastric cancer. The main purpose of this study is to investigate the efficacy and safety of thalidomide and CPT-11 in advanced gastric cancer. The investigators will also manage to find out the possible interactions between CPT-11 pharmacokinetics and thalidomide to explain the previously described gastrointestinal toxicity reduction.